RARE Ultragenyx Pharmaceutical Inc.
Company Analysis
Latest News
Ultragenyx to Sell Priority Review Voucher for $203 Million in Cash
Ultragenyx Pharmaceutical Inc. has entered into a material agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million. The...
Ultragenyx Announces Sale of Priority Review Voucher for $210 Million
Ultragenyx Pharmaceutical Inc. has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million in cash....
🔴 Ultragenyx is trading 5% down
Ultragenyx is trading 5.45% lower at $14.39, with no new company announcement clearly tied to the October 5 intraday decline. - The Phase 3 Aspire study in...
🟢 Ultragenyx is trading 5.8% up
Ultragenyx is trading 5.8% higher at $15.25, with no clear company-specific catalyst identified for the move. - Recent coverage centers on the FAYUVI FDA...
🔴 Ultragenyx is trading 5.32% down today amid market pressure and a pullback after gains
Ultragenyx is trading 5.32% down at $14.79 as broader risk-off sentiment weighs on equities. - Nasdaq is down 1.00% and S&P 500 is down 0.55%; biotech is...
🟢 Ultragenyx is trading 5.8% up today as investors reprice FAYUVI approval
Ultragenyx is trading 5.8% up at $15.49 as investors continue repricing the company following the September 17, 2026 FDA approval of FAYUVI, the first approved...
Ultragenyx Announces FDA Full Approval for FAYUVI™, First-Ever Gene Therapy for MPS IIIA
Ultragenyx Pharmaceutical Inc. announced it received standard full approval from the U.S. Food and Drug Administration (FDA) for FAYUVI™ (rebisufligene...
🟢 Ultragenyx is trading 11.57% up today as XBI rises amid renewed M&A optimism
Ultragenyx is trading at $14.37, up 11.57%, as biotechnology rebounds and XBI rises 2.55%. • The rebound reflects a stronger industry outlook and renewed M&A...
🟢 Ultragenyx is trading 5.5% up today amid a broad biotechnology rebound
Ultragenyx is trading 5.5% up at $13.59, alongside a broad biotechnology rebound and stronger overall risk appetite. - No new company-specific announcement...
🟢 Ultragenyx is trading 5% up today as rebound appears to reflect post-selloff trading
Ultragenyx is trading 5% up at $15.62, rebounding after its September 3, 2026 close of $14.85, when shares fell 44.03%. - The earlier collapse followed...
🔴 Ultragenyx is trading 47% down today after apazunersen fails Phase 3 Aspire trial
Ultragenyx is trading 47% down at $14.03 after apazunersen (GTX-102) failed its Phase 3 Aspire trial in Angelman syndrome. - The treatment missed both its...
Ultragenyx's Angelman Drug Fails Its Biggest Test — Now What Is Left to Support a $1.4 Billion Company?
Shares of Ultragenyx Pharmaceutical cratered 45% overnight after its most-watched experimental therapy — a gene-silencing drug for Angelman syndrome, a rare...
🔴 Ultragenyx is trading 45.53% down in pre-market after Phase 3 Aspire study failed primary endpoints
Ultragenyx is trading at $14.45 (-45.53%) in pre-market after its Phase 3 Aspire study of apazunersen failed to meet primary and key secondary endpoints. -...
Ultragenyx's Phase 3 Angelman Syndrome Trial for Apazunersen Fails to Meet Endpoints
Ultragenyx Pharmaceutical Inc. announced that its Phase 3 Aspire study for apazunersen (GTX-102) in patients with Angelman syndrome did not meet its primary or...
🔴 Ultragenyx is trading 43% down in after-hours trading
Ultragenyx is trading 42.82% down at $15.17 after-hours on September 2, 2026, versus the regular-session close; the catalyst remains unclear. - No credible...
🟢 Ultragenyx is trading 4.1% up today after GENGLYCOS FDA approval
Ultragenyx is trading at $26.79 (+4.14%) after the August 19 FDA approval of GENGLYCOS, its first approved gene therapy. - Reuters reported the announcement...
🟢 Ultragenyx is trading 4.64% up today after FDA’s accelerated approval of GENGLYCOS
Ultragenyx is trading 4.64% up now at $26.50 as investors continue responding to the FDA’s accelerated approval of GENGLYCOS, announced August 19, 2026. - The...
🔴 Ultragenyx is trading 4.23% down today amid broader biotech pullback
Ultragenyx is trading 4.23% down at $25.13 amid a broader biotech pullback and weak risk sentiment across U.S. equities. - Ultragenyx announced accelerated...
Ultragenyx Stock Falls, Awaiting FDA Decision on Rare Disease Gene Therapy
Ultragenyx Pharmaceutical (RARE) shares fell for a second consecutive day on Tuesday, August 18th. Investors are awaiting an FDA decision on DTX401, a gene...
Ultragenyx Lands Its First Gene Therapy — But Can a Tiny Patient Pool Justify the Stock's Leap of Faith?
Shares of Ultragenyx surged 14% to $29.91 after the FDA granted accelerated approval for the company's first-ever gene therapy, a one-time treatment for a rare...